---
title: "Q32 Bio Inc. (QTTB.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/QTTB.US.md"
symbol: "QTTB.US"
name: "Q32 Bio Inc."
industry: "Biotechnology"
datetime: "2026-06-14T02:03:24.499Z"
locales:
  - [en](https://longbridge.com/en/quote/QTTB.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/QTTB.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/QTTB.US.md)
---

# Q32 Bio Inc. (QTTB.US)

## Company Overview

Q32 Bio Inc., a clinical-stage biotechnology company, develops novel biologics to restore healthy immune balance in patients with alopecia areata and other autoimmune and inflammatory diseases driven by pathological immune dysfunction. The company is developing Bempikibart (ADX-914), a fully human anti–interleukin-7 receptor alpha antagonist monoclonal antibody which completed Phase 2a clinical trials, designed to re-regulate adaptive immune function by blocking signaling mediated by interleukin-7 and thymic stromal lymphopoietin for the treatment of atopic dermatitis and alopecia areata. It also develops ADX-096, a C3d mAb – CR1 fusion protein for use in ophthalmologic indications, as well as other C3d mAb fusions and nanobodies designed for tissue-targeted complement inhibition and a range of other indications. The company was founded in 2017 and is based in Waltham, Massachusetts.

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Exchange | US Market |
| Website | [www.q32bio.com](https://www.q32bio.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: B
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-06-13T04:30:13.000Z

**Overall: B (0.39)**

**Industry**: Biotechnology

| Metric | Value |
|--------|-------|
| Industry Ranking | 46 / 390 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Blend - Stocks in which the company has both growth and mature businesses.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: B

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 0.00% |  |
| Net Profit YoY | 155.60% |  |
| P/B Ratio | 4.63 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 214329085.60 |  |
| Revenue | 53737000.00 |  |

#### Multi Score Score: B

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 157.18% | A |
| Profit Margin | 61.86% | A |
| Gross Margin | 0.00% | E |
| Revenue YoY | 0.00% | D |
| Net Profit YoY | 155.60% | A |
| Total Assets YoY | -19.47% | E |
| Net Assets YoY | 1253.79% | A |
| Cash Flow Margin | -82.44% | E |
| OCF YoY | 0.00% | D |
| Turnover | 0.75 | B |
| Gearing Ratio | 27.27% | B |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Q32 Bio Inc.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "0.00%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "155.60%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "4.63",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "214329085.60",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "53737000.00",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "B",
      "indicators": [
        {
          "name": "ROE",
          "value": "157.18%",
          "rating": "A"
        },
        {
          "name": "Profit Margin",
          "value": "61.86%",
          "rating": "A"
        },
        {
          "name": "Gross Margin",
          "value": "0.00%",
          "rating": "E"
        },
        {
          "name": "Revenue YoY",
          "value": "0.00%",
          "rating": "D"
        },
        {
          "name": "Net Profit YoY",
          "value": "155.60%",
          "rating": "A"
        },
        {
          "name": "Total Assets YoY",
          "value": "-19.47%",
          "rating": "E"
        },
        {
          "name": "Net Assets YoY",
          "value": "1253.79%",
          "rating": "A"
        },
        {
          "name": "Cash Flow Margin",
          "value": "-82.44%",
          "rating": "E"
        },
        {
          "name": "OCF YoY",
          "value": "0.00%",
          "rating": "D"
        },
        {
          "name": "Turnover",
          "value": "0.75",
          "rating": "B"
        },
        {
          "name": "Gearing Ratio",
          "value": "27.27%",
          "rating": "B"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | 6.45 | 21/390 | 3.58 | 3.09 | 2.77 |
| PB | 4.63 | 316/390 | 2.54 | 2.19 | 1.97 |
| PS (TTM) | 3.99 | 90/390 | 1.99 | 1.79 | 1.56 |
| Dividend Yield | 0.00% | - | - | - | - |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Kiniksa Pharmaceuticals (KNSA.US) | B | A | A | B | A | A |
| 02 | Arbutus Pharma (ABUS.US) | A | A | A | A | B | A |
| 03 | Rigel Pharma (RIGL.US) | A | A | B | A | B | A |
| 04 | CapForce Inc. (CFOR.US) | A | A | A | A | B | A |
| 05 | OpGen (OPGN.US) | B | A | A | A | B | A |

## Institutional View

### Analyst Rating Distribution

> As of 2026-05-22T04:00:00.000Z

Total Analysts: **5**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 4 | 80% |
| Hold | 1 | 20% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 12.64 |
| Highest Target | 20.00 |
| Lowest Target | 10.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/QTTB.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/QTTB.US/norm.md)
- [Related News](https://longbridge.com/en/quote/QTTB.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/QTTB.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**